Affinage

SLC7A11

Cystine/glutamate transporter · UniProt Q9UPY5

Length
501 aa
Mass
55.4 kDa
Annotated
2026-04-28
100 papers in source corpus 44 papers cited in narrative 44 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SLC7A11 (xCT) is the substrate-specific light chain of system xc⁻, a cystine/glutamate antiporter that drives glutathione biosynthesis, suppresses ferroptosis, and modulates lysosomal pH homeostasis. Disulfide-linked to its obligate heavy chain SLC3A2 (4F2hc), SLC7A11 exchanges extracellular cystine for intracellular glutamate at a 1:1 ratio, providing the rate-limiting cysteine precursor for glutathione synthesis; it additionally transports kynurenine to propagate NRF2-dependent anti-ferroptotic signaling to neighboring cells (PMID:21369940, PMID:35245456). SLC7A11 also resides on lysosomes where it mediates a slow proton leak through flux of protonatable substrates (cystine and glutamate), and its loss causes lysosomal over-acidification, impaired degradation, and neuronal α-synuclein aggregation (PMID:40280132). SLC7A11 protein abundance and activity are controlled by a convergent regulatory network: transcriptionally by NRF2, ATF4, ETS-1, SOX2, STAT3, CEBPG, and NFATc1 (PMID:31000598, PMID:36996941, PMID:34385181); post-translationally by multiple E3 ligases (SOCS2, TRIM3, ZRANB1) and deubiquitinases (USP52, OTUB1, DUBA) that tune K48- and K11-linked ubiquitination, as well as by S-palmitoylation at Cys327, O-GlcNAcylation at Ser26, SUMOylation, and UFMylation (PMID:35995846, PMID:37978273, PMID:38211651, PMID:37867237, PMID:34162423); and at the mRNA level by METTL3/IGF2BP1-mediated m6A stabilization and RBMS1-bridged translational enhancement (PMID:35522946, PMID:34609966).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 2011 High

    Establishing the molecular identity and transport mechanism of SLC7A11 resolved how cells acquire cystine for glutathione synthesis: SLC7A11 forms system xc⁻ with SLC3A2 via a disulfide bond and mediates obligate 1:1 cystine/glutamate antiport.

    Evidence Biochemical characterization and functional transport assays across multiple labs

    PMID:21369940

    Open questions at the time
    • Structure of the heterodimeric transporter at atomic resolution was not yet available
    • Regulation of transporter trafficking to the plasma membrane was unknown
  2. 2015 High

    Defining the true electrophoretic mobility (35 kDa) and brain-wide distribution of SLC7A11 corrected widespread antibody misidentification and established its neural expression pattern.

    Evidence Western blotting with xCT-knockout mouse brain as negative control; immunohistochemistry across forebrain regions

    PMID:26494316

    Open questions at the time
    • Cell-type-specific expression within brain regions not resolved
    • Functional role in neurons vs. glia not delineated
  3. 2019 High

    Identification of oncogenic KRAS-driven transcriptional upregulation of SLC7A11 via ETS-1 (in synergy with ATF4) established how tumors co-opt the cystine uptake axis for redox defense during transformation.

    Evidence Transcriptomics, promoter transactivation assays, shRNA knockdown, xenograft models

    PMID:31000598

    Open questions at the time
    • Whether other RAS effector branches independently regulate SLC7A11 was not tested
    • Relative contributions of ETS-1 vs. ATF4 in different tumor types remained unclear
  4. 2019 High

    Demonstrating that IFNγ from CD8⁺ T cells and ATM-activated radiotherapy converge to repress SLC7A11 linked adaptive immunity and DNA damage signaling to tumor ferroptosis.

    Evidence In vitro signaling assays combined with tumor models and pharmacological/genetic SLC7A11 manipulation

    PMID:31554642

    Open questions at the time
    • Direct transcription factor(s) mediating IFNγ-dependent SLC7A11 repression not identified in this study
    • Contribution of other immune cell types not assessed
  5. 2020 High

    Cardiomyocyte-specific overexpression of Slc7a11 preventing cardiac ferroptosis established that SLC7A11-dependent GSH synthesis is rate-limiting for redox homeostasis in the heart.

    Evidence Conditional Fth knockout mice, cardiomyocyte Slc7a11 overexpression, GSH measurement, ferrostatin-1 rescue

    PMID:32349646

    Open questions at the time
    • Whether endogenous cardiac SLC7A11 levels are dynamically regulated during ischemia-reperfusion was not tested
  6. 2021 High

    Multiple transcription factors and epigenetic regulators were shown to directly control SLC7A11 promoter activity — ATF4 in hepatocytes, SOX2 (redox-sensitive Cys265) in lung cancer stem cells, EZH2-mediated H3K27me3, and KDM4A-mediated H3K9me3 demethylation — revealing a multi-layered transcriptional control architecture.

    Evidence Conditional ATF4-KO hepatocytes with SLC7A11 reconstitution; SOX2 Cys265 mutagenesis and reporter assays; ChIP for H3K27me3 (EZH2/HBx) and H3K9me3 (KDM4A) at the SLC7A11 promoter

    PMID:33689883 PMID:34385181 PMID:34615538 PMID:36996941

    Open questions at the time
    • Combinatorial or hierarchical relationships among these transcription factors were not determined
    • Chromatin state-specific regulation across tissue types not systematically compared
  7. 2021 Medium

    Identification of the first post-translational stability regulators — OTUB1 deubiquitinase and UFMylation — established that SLC7A11 protein turnover is actively controlled by the ubiquitin-proteasome system.

    Evidence Co-IP and ubiquitination assays (OTUB1); immunoprecipitation-based UFMylation assay with metformin inhibition

    PMID:34162423 PMID:34927544

    Open questions at the time
    • Specific UFMylation site(s) on SLC7A11 not mapped
    • OTUB1 finding from single lab without independent replication
    • UFMylation machinery components directly acting on SLC7A11 not identified
  8. 2021 High

    RBMS1 was identified as a translational enhancer of SLC7A11 mRNA by bridging its 3′- and 5′-UTR through interaction with eIF3d, revealing a post-transcriptional regulatory layer.

    Evidence shRNA screen, RNA pulldown, Co-IP (RBMS1–eIF3d), cystine uptake assays, in vivo models

    PMID:34609966

    Open questions at the time
    • Whether other eIF3 subunits participate was not tested
    • Structural basis of UTR bridging unknown
  9. 2022 High

    Discovery that SLC7A11 imports kynurenine — beyond cystine — expanded its substrate repertoire and revealed a paracrine anti-ferroptotic circuit: IDO1-expressing cells export kynurenine, which SLC7A11 imports into receiver cells to activate NRF2 and further upregulate SLC7A11 itself.

    Evidence Metabolic tracing, SLC7A11 knockout/knockdown, pharmacological inhibition, NRF2 reporter assays

    PMID:35245456

    Open questions at the time
    • Kynurenine transport kinetics relative to cystine not quantified
    • Whether other system xc⁻ substrates exist remains open
  10. 2022 High

    SOCS2 was identified as a K48-linked E3 ubiquitin ligase adaptor for SLC7A11 (via SH2 domain recognition of the N-terminal domain), and METTL3-mediated m6A on SLC7A11 mRNA was shown to recruit IGF2BP1 to stabilize the transcript by blocking deadenylation, establishing converging protein- and mRNA-level stability mechanisms.

    Evidence Co-IP, domain mapping, ubiquitination assays, xenograft models (SOCS2); MeRIP-qPCR, RIP, RACE-PAT assay (IGF2BP1/METTL3)

    PMID:35522946 PMID:35995846

    Open questions at the time
    • Whether SOCS2 and other E3 ligases compete for the same SLC7A11 pool not examined
    • Relative contributions of different m6A readers (IGF2BP1 vs. IGF2BP2) not directly compared
  11. 2022 High

    SLC7A11 was found to act as a metabolic brake on dendritic cell efferocytosis: its inhibition or deletion shifts DCs toward aerobic glycolysis and enhances apoptotic cell clearance, linking SLC7A11 to innate immune function beyond redox control.

    Evidence Conditional knockout, siRNA, pharmacological inhibition, transcriptomics, glycogen metabolism assays, mouse wound healing model

    PMID:35614212

    Open questions at the time
    • Molecular mechanism by which SLC7A11 activity restrains glycolytic reprogramming not fully resolved
    • Whether this extends to macrophage efferocytosis not tested
  12. 2022 High

    CD44v8-10 was shown to bind and stabilize SLC7A11 at the cell surface, and secreted AGR2 from neutrophils activates xCT via the CD98hc partner, revealing extracellular regulation of transporter complex assembly.

    Evidence Cell surface expression analysis, pharmacological inhibition, Sugen/hypoxia model (CD44v); Co-IP, neutrophil-specific Agr2 KO, in vivo metastasis (AGR2)

    PMID:30897333 PMID:35086885

    Open questions at the time
    • Structural basis of CD44v–SLC7A11 interaction not determined
    • Whether AGR2 directly modulates transport kinetics unknown
  13. 2023 High

    Site-specific ubiquitination mapping expanded: TRIM3 was shown to catalyze K11-linked ubiquitination at K37, and ZRANB1 was found to function as a non-canonical E3 ligase for SLC7A11 (via residues 463–584), establishing that multiple ubiquitin chain types regulate SLC7A11 degradation.

    Evidence Co-IP, site-directed mutagenesis, ubiquitination assays, DUB sgRNA screen, in vivo tumor models

    PMID:37831441 PMID:37978273

    Open questions at the time
    • Whether K11 and K48 chains are deposited on the same or different SLC7A11 pools unclear
    • How cells select among competing E3 ligases not addressed
  14. 2023 High

    O-GlcNAcylation of SLC7A11 at Ser26 by OGT was shown to be essential for cystine import, establishing a nutrient-sensing PTM that directly controls transporter function, with upstream USP8/SLK-dependent stabilization of OGT.

    Evidence Mass spectrometry, site-directed mutagenesis, O-GlcNAcylation assays, cystine uptake assays, xenograft models

    PMID:37867237

    Open questions at the time
    • Whether O-GlcNAcylation affects SLC7A11 conformational dynamics or surface retention not distinguished
    • Relationship to other PTMs on adjacent residues unknown
  15. 2024 High

    S-palmitoylation at Cys327 by ZDHHC8 was shown to stabilize SLC7A11 by reducing its ubiquitination, with AMPKα1-mediated phosphorylation of ZDHHC8 at S299 strengthening the interaction — revealing a PTM crosstalk axis that integrates energy sensing with ferroptosis resistance.

    Evidence Palmitoylation assays, Cys327/S299 mutagenesis, in vitro kinase assay, ubiquitination assays, xenograft models

    PMID:38211651

    Open questions at the time
    • Whether palmitoylation affects SLC7A11 membrane microdomain partitioning not examined
    • Interplay between palmitoylation and O-GlcNAcylation on the same molecule not tested
  16. 2024 High

    SPTBN2 spectrin was identified as a trafficking adaptor connecting SLC7A11 (via its CH domain) to the Arp1 motor complex, establishing the first mechanism for directed membrane delivery of SLC7A11.

    Evidence Co-IP, CH domain mapping, membrane fractionation, cystine uptake assays, in vivo xenograft

    PMID:38241838

    Open questions at the time
    • Whether SPTBN2 also controls SLC7A11 endocytic retrieval not tested
    • Arp1 motor complex involvement not independently validated
  17. 2024 High

    USP52/PAN2 was identified as a deubiquitinase that cleaves K48-linked chains at K4 and K12 of SLC7A11, and SUMOylation by PIAS4 was shown to stabilize SLC7A11, further expanding the repertoire of PTMs governing SLC7A11 stability.

    Evidence siRNA DUB screen, K-to-R mutagenesis, ubiquitin chain linkage analysis (USP52); Ni-bead SUMOylation pulldown, Co-IP, ChIP (PIAS4)

    PMID:38615741 PMID:39392373

    Open questions at the time
    • Whether USP52 and OTUB1 act redundantly or in distinct compartments not compared
    • Specific SUMO isoform(s) conjugated to SLC7A11 not identified
  18. 2024 Medium

    SLC7A11-mediated cystine import was linked to disulfidptosis — a distinct, non-ferroptotic cell death — when TXNRD1 is inhibited; high SLC7A11 causes intracellular cystine accumulation and disulfide stress in cytoskeletal proteins, with BAP1 epigenetically repressing SLC7A11 to protect against this pathway.

    Evidence NFATc1 ChIP/reporter assays, TXNRD1 inhibitor rescue with SLC7A11 inhibitors, BAP1 genetic epistasis experiments

    PMID:37148740 PMID:39266549

    Open questions at the time
    • Which cytoskeletal disulfide bonds are critical for cell death not mapped
    • Physiological contexts where disulfidptosis dominates over ferroptosis not delineated
  19. 2025 High

    SLC7A11 was discovered to function as a lysosomal proton leak channel through flux of cystine and glutamate, revealing a second subcellular site of action; SLC7A11 deficiency causes lysosomal over-acidification, impaired degradation, and α-synuclein aggregation in neurons.

    Evidence Orphan lysosomal membrane protein screen, lysosomal pH measurements, genetic knockout, pharmacological inhibition, neuronal ferroptosis assays

    PMID:40280132

    Open questions at the time
    • How SLC7A11 is sorted between plasma membrane and lysosomal pools not determined
    • Whether lysosomal SLC7A11 also transports kynurenine unknown
  20. 2025 High

    Galectin-13, secreted by ferroptotic cells, was shown to bind CD44 on neighboring cells and inhibit SLC7A11 membrane localization, establishing a paracrine ferroptosis propagation mechanism.

    Evidence Secreted protein identification, Galectin-13–CD44 binding assays, SLC7A11 membrane fractionation, FOXK1 phosphorylation assay, synthetic mimetic peptide

    PMID:40246981

    Open questions at the time
    • Structural basis of Galectin-13–CD44 interaction not resolved
    • Whether Galectin-13 affects other membrane transporters not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include how SLC7A11 is sorted between plasma membrane and lysosomal compartments, whether PTM crosstalk (palmitoylation, O-GlcNAcylation, ubiquitination, SUMOylation) occurs on the same molecules or distinct pools, and the structural basis for substrate promiscuity (cystine, glutamate, kynurenine).
  • No high-resolution structure of mammalian SLC7A11–SLC3A2 heterodimer with bound substrates
  • Compartment-specific interactome not mapped
  • In vivo significance of lysosomal SLC7A11 function in non-neuronal tissues unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005215 transporter activity 3 GO:0140104 molecular carrier activity 1
Localization
GO:0005886 plasma membrane 4 GO:0005764 lysosome 1
Pathway
R-HSA-392499 Metabolism of proteins 5 R-HSA-5357801 Programmed Cell Death 5 R-HSA-382551 Transport of small molecules 3 R-HSA-1430728 Metabolism 2 R-HSA-168256 Immune System 2
Partners
OTUB1SLC3A2SOCS2SPTBN2TRIM3USP52ZDHHC8ZRANB1
Complex memberships
system xc⁻ (SLC7A11/SLC3A2)

Evidence

Reading pass · 44 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2025 SLC7A11 functions as an unconventional H+ transporter in lysosomes, mediating a slow lysosomal proton leak through downward flux of cystine and glutamate (two H+ equivalents with large but opposite concentration gradients). SLC7A11 deficiency or inhibition causes lysosomal over-acidification, reduced degradation, accumulation of storage materials, ferroptosis, and facilitates α-synuclein aggregation in neurons. Orphan lysosome membrane protein candidate screen, lysosomal pH measurements, genetic knockout, pharmacological inhibition, live-cell imaging, fractionation, neuronal ferroptosis assays Cell High 40280132
2011 SLC7A11 (xCT) forms the specific light chain of system xc-, linked by a disulfide bridge to the heavy chain 4F2 (SLC3A2), and transports cystine into cells in exchange for glutamate at a 1:1 ratio; intracellular cystine is reduced to cysteine, the rate-limiting precursor for glutathione synthesis. Biochemical characterization, functional transport assays, review of molecular biology of xCT/4F2 complex Amino acids High 21369940
2019 Oncogenic KRAS upregulates SLC7A11 (xCT) transcription via the ETS-1 transcription factor (downstream of RAS-RAF-MEK-ERK) in synergy with ATF4; xCT-mediated cystine uptake maintains GSH levels and is required for KRAS-mediated oncogenic transformation in vitro and in vivo. Whole transcriptome analysis, promoter transactivation assays, shRNA knockdown, xenograft tumor models Proceedings of the National Academy of Sciences of the United States of America High 31000598
2019 IFNγ from CD8+ T cells and radiotherapy-activated ATM independently and synergistically suppress SLC7A11, reducing cystine uptake and enhancing tumor lipid oxidation and ferroptosis. In vitro signaling assays, tumor models with ferroptosis agonists/antagonists, genetic and pharmacological manipulation of SLC7A11 Cancer discovery High 31554642
2022 SLC7A11 imports kynurenine (KYN) from IDO1-expressing cells into non-IDO1-expressing 'receiver' cells; once inside, KYN is converted to downstream metabolites that suppress ferroptosis by ROS scavenging and activating an NRF2-dependent, AHR-independent cell-protective pathway including SLC7A11 itself, propagating anti-ferroptotic signaling. Metabolic tracing, genetic knockdown/knockout of SLC7A11, pharmacological inhibition, NRF2 reporter assays Molecular cell High 35245456
2022 SOCS2 acts as an E3 ubiquitin ligase adaptor that recognizes the N-terminal domain of SLC7A11 via its SH2 domain and recruits elongin B/C to promote K48-linked polyubiquitination and proteasomal degradation of SLC7A11, leading to ferroptosis. Co-immunoprecipitation, domain mapping, ubiquitination assays, in vivo xenograft models Cell death and differentiation High 35995846
2023 TRIM3 E3 ubiquitin ligase directly interacts with SLC7A11 through its NHL domain and promotes K11-linked ubiquitination of SLC7A11 at K37, leading to proteasome-mediated SLC7A11 degradation and ferroptosis in NSCLC. Co-immunoprecipitation, ubiquitination assays, domain mapping, in vivo tumor models Cell death and differentiation High 37978273
2023 ZRANB1, normally considered a deubiquitinase, functions as an E3 ubiquitin ligase for SLC7A11 via a non-canonical catalytic domain (residues 463–584); it ubiquitinates and represses SLC7A11 expression, inhibits GSH synthesis, and promotes ferroptosis. DUB sgRNA whole-genome screen, Co-IP, ubiquitination assays, domain deletion mutagenesis, lipid peroxidation assays The Journal of cell biology High 37831441
2024 ZDHHC8, a palmitoyl transferase, catalyzes S-palmitoylation of SLC7A11 at Cys327, which stabilizes SLC7A11 protein by decreasing its ubiquitination. AMPKα1 phosphorylates ZDHHC8 at S299 to strengthen the ZDHHC8–SLC7A11 interaction, promoting palmitoylation and ferroptosis resistance in glioblastoma. Co-immunoprecipitation, mutagenesis (Cys327, S299), palmitoylation assays, ubiquitination assays, in vitro kinase assay, xenograft models Cancer letters High 38211651
2023 USP8 stabilizes OGT (O-GlcNAc transferase) by inhibiting K48-linked polyubiquitination at OGT K117; SLK-mediated phosphorylation of USP8 at S716 is required for USP8–OGT interaction. OGT then O-GlcNAcylates SLC7A11 at Ser26, which is essential for SLC7A11-mediated cystine import. Co-immunoprecipitation, mass spectrometry, site-directed mutagenesis, O-GlcNAcylation assays, cystine uptake assays, xenograft models Advanced science High 37867237
2024 SPTBN2 interacts with SLC7A11 via its CH domain and connects it to the motor protein Arp1, facilitating membrane localization of SLC7A11, which is required for its cystine transport (System Xc-) activity and GSH synthesis. Loss of SPTBN2 reduces SLC7A11 membrane trafficking and sensitizes NSCLC to ferroptosis. Co-immunoprecipitation, domain mapping (CH domain), fractionation/membrane localization assays, cystine uptake assays, in vivo xenograft Redox biology High 38241838
2024 USP52/PAN2 deubiquitylase interacts with SLC7A11 and cleaves K48-conjugated ubiquitin chains at K4 and K12 of SLC7A11, enhancing its protein stability; USP52 depletion promotes SLC7A11 degradation, reduces GSH synthesis, and increases ferroptosis in bladder cancer. siRNA deubiquitylase screen, Co-immunoprecipitation, ubiquitin chain linkage analysis, site-directed mutagenesis, in vivo models Advanced science High 39392373
2021 UFMylation of SLC7A11 (a post-translational modification by UFM1) is required for SLC7A11 protein stability; metformin inhibits UFMylation of SLC7A11, reducing its protein stability and promoting ferroptosis in breast cancer cells. Immunoprecipitation, UFMylation assay, protein stability assays, ferroptosis markers (Fe2+, lipid ROS, GSH), in vivo tumor model Journal of experimental & clinical cancer research Medium 34162423
2021 RBMS1 RNA-binding protein interacts directly with translation initiation factor eIF3d and bridges the 3'- and 5'-UTR of SLC7A11 mRNA to enhance its translation; RBMS1 ablation inhibits SLC7A11 translation, reduces cystine uptake, and promotes ferroptosis in lung cancer. shRNA screen, RNA pulldown, Co-IP (RBMS1–eIF3d interaction), cystine uptake assays, in vivo models The Journal of clinical investigation High 34609966
2022 IGF2BP1 acts as an m6A reader for SLC7A11 mRNA; METTL3-mediated m6A modification of SLC7A11 mRNA recruits IGF2BP1, which blocks BTG2/CCR4-NOT complex recruitment by competing for PABPC1 binding, thereby inhibiting SLC7A11 mRNA deadenylation and enhancing its stability and expression. MeRIP-qPCR, dual luciferase reporter, RNA pulldown, RIP, RACE-PAT assay Clinical and translational medicine High 35522946
2023 ATF4 transcription factor directly induces SLC7A11 (xCT) expression to maintain glutathione production and prevent ferroptosis in hepatocytes; reconstitution of SLC7A11 in ATF4-deficient hepatocytes and mouse livers reversed ferroptosis susceptibility and hepatocarcinogenesis. Conditional hepatocyte-specific ATF4 knockout mice, SLC7A11 reconstitution (ectopic expression), RNA-sequencing, biochemical ferroptosis markers Journal of hepatology High 36996941
2021 HBx protein promotes EZH2-mediated H3K27 trimethylation at the SLC7A11 promoter, suppressing SLC7A11 expression and facilitating hepatocyte ferroptosis in acute liver failure; EZH2 inhibition or SLC7A11 overexpression rescues this phenotype. Chromatin immunoprecipitation (ChIP), Co-IP, in vitro hepatocyte injury model, HBx transgenic mice, gene overexpression Journal of biomedical science High 34615538
2021 KDM4A histone demethylase controls H3K9me3 demethylation at the SLC7A11 promoter region, positively regulating SLC7A11 transcription; KDM4A knockdown reduces SLC7A11 expression and promotes ferroptosis in osteosarcoma. ChIP assay, shRNA knockdown, in vivo tumor models, ferroptosis markers Biochemical and biophysical research communications Medium 33689883
2021 SOX2 transcription factor directly binds to and activates the SLC7A11 promoter in lung cancer stem-like cells, upregulating SLC7A11 and conferring ferroptosis resistance; oxidation of SOX2 at Cys265 inhibits its activity and decreases SLC7A11 expression. Promoter mutation analysis, luciferase reporter assay, SOX2 Cys265 mutagenesis, in vivo tumor models Cancer research High 34385181
2022 CD44 variant isoform CD44v8-10 binds to and stabilizes xCT (SLC7A11) on the cell surface of EndMT-derived cells in pulmonary arterial hypertension, enhancing antioxidant defense via glutathione production; pharmacological inhibition of xCT with sulfasalazine reduces these cells and attenuates pulmonary hypertension. In vitro EndMT model, cell surface xCT expression analysis, pharmacological inhibition, Sugen5416/hypoxia mouse model, flow cytometry American journal of respiratory cell and molecular biology Medium 30897333
2022 Secreted AGR2 from tumor-associated neutrophils binds to CD98hc (SLC3A2, the heavy chain partner of SLC7A11) as a functional receptor, increasing xCT (SLC7A11) activity in a CD98hc-dependent manner, subsequently activating the RhoA/ROCK2 cascade to promote colorectal cancer metastasis. Co-IP, neutrophil-specific Agr2 knockout mice, in vitro and in vivo functional assays, signaling pathway analysis Gut High 35086885
2022 SLC7A11 acts as a molecular brake on efferocytosis in dendritic cells; its pharmacological inhibition, deletion, or knockdown enhances efferocytosis by shifting dendritic cells toward aerobic glycolysis using glucose from glycogen stores; SLC7A11 deficiency-enhanced efferocytosis leads to TGFβ family member GDF15 release and accelerated wound healing. Pharmacological inhibition, conditional knockout, siRNA knockdown, transcriptomics, glucose/glycogen metabolism assays, mouse wound healing model, scRNA-seq of inflamed skin Nature High 35614212
2020 Overexpression of Slc7a11 in cardiomyocytes increases GSH levels and prevents cardiac ferroptosis; Fth-deficient cardiomyocytes have reduced Slc7a11 expression, indicating Fth regulates Slc7a11 to maintain antioxidant capacity. Conditional Fth knockout mice, cardiomyocyte-specific Slc7a11 overexpression, GSH measurements, ferrostatin-1 rescue, lipid peroxidation assays Circulation research High 32349646
2022 STAT6 competitively binds to CBP acetyltransferase, inhibiting p53 acetylation, which transcriptionally restores SLC7A11 expression; this mechanism negatively regulates ferroptosis in lung epithelial cells during acute lung injury. ChIP, co-immunoprecipitation, STAT6 conditional knockout mice, overexpression, ferroptosis markers Cell death & disease Medium 35668064
2024 PHGDH binds to PCBP2 (RNA-binding protein) and inhibits its ubiquitination-mediated degradation; stabilized PCBP2 in turn stabilizes SLC7A11 mRNA, increasing its expression and inhibiting ferroptosis in bladder cancer. Co-IP, mass spectrometry, RIP assay, ubiquitination assay, gene knockdown International journal of biological sciences Medium 36147463
2022 LncRNA HEPFAL promotes SLC7A11 protein ubiquitination and degradation, reducing SLC7A11 stability and increasing ferroptosis in hepatocellular carcinoma; this effect is linked to mTORC1 pathway. Western blot, ubiquitination assay, siRNA knockdown, ferroptosis marker measurement Cell death & disease Medium 36008384
2021 OTUB1 deubiquitinase directly interacts with SLC7A11 and stabilizes it by reducing its ubiquitin-mediated degradation; OTUB1 knockdown triggers ferroptosis in a SLC7A11-dependent manner and reduces glioma cell stemness. Co-IP, ubiquitination assays, ectopic SLC7A11 expression rescue, sphere-formation assays Bioengineered Medium 34927544
2024 TANSHINONE IIA decreases KDM1A expression, suppressing KDM1A-driven transcription of PIAS4; reduced PIAS4 decreases direct SUMOylation of SLC7A11 (PIAS4 binds directly to SLC7A11), destabilizing SLC7A11 and promoting ferroptosis in breast cancer. Ni-bead pulldown SUMOylation assay, Co-IP, ChIP, luciferase assay, in vivo xenograft Journal of advanced research Medium 38615741
2024 p62 protein directly binds SLC7A11; sulforaphane targets p62 and enhances the p62–SLC7A11 protein-protein interaction, promoting lysosomal (autolysosomal) degradation of SLC7A11 and triggering ferroptosis in osteosarcoma. Protein-protein interaction assay, lysosomal degradation pathway analysis, ferroptosis marker measurement, in vivo subcutaneous and intratibial OS models Redox biology Medium 39657365
2025 Galectin-13, secreted by cells undergoing ferroptosis, binds to CD44 on neighboring cells and inhibits plasma membrane localization of SLC7A11, thereby accelerating neighboring cell death and propagating ferroptosis. FOXK1, phosphorylated by PKCβII, facilitates Galectin-13 expression and secretion during ferroptotic cell death. Secreted protein identification, binding assays (Galectin-13 to CD44), membrane fractionation of SLC7A11, FOXK1 phosphorylation assay, ferroptosis propagation assays, synthetic Galectin-13 mimetic peptide Nature chemical biology High 40246981
2024 DUBA deubiquitinase stabilizes SLC7A11 protein in differentiated cells; SLC7A11-derived cysteine increases c-Myc expression, linking the DUBA–SLC7A11–c-Myc axis to cancer stemness and ferroptosis resistance. Deubiquitination assay, Co-IP, cysteine supplementation, c-Myc expression assay, cancer stem cell differentiation models Oncogene Medium 37537342
2024 HTRA1 serine protease interacts with SLC7A11 through its Kazal structural domain and upregulates SLC7A11 expression, inhibiting ferroptosis and promoting chemoresistance in colorectal cancer. Co-IP, domain mapping (Kazal domain), ferroptosis marker assays, electron microscopy, gain/loss-of-function analysis Cell death discovery Medium 38740771
2024 FMRP (Fragile X Mental Retardation Protein) interacts with splicing factor hnRNPM to promote exon-skipping alternative splicing of SLC7A11, generating an SLC7A11-S splicing variant that promotes ferroptosis resistance; FMRP also catalyzes m6A modification of SLC7A11 mRNA through METTL3 to enhance translation. RNA pulldown, mass spectrometry, splicing assays, m6A methylation analysis, Co-IP (FMRP–hnRNPM), ferroptosis assays, in vivo models Redox biology Medium 39388855
2015 xCT (SLC7A11) protein migrates at 35 kDa (not the predicted 55.5 kDa) on Western blots, as confirmed using xCT-knockout mouse brain extracts as negative controls; xCT protein is expressed throughout mouse forebrain (cortex, striatum, hippocampus, midbrain, thalamus, amygdala) with highest expression in regions facing CSF and meninges. Western blotting with xCT(-/-) knockout mouse negative controls, immunohistochemistry on brain tissue sections The Journal of comparative neurology High 26494316
2024 NFATc1 transcription factor directly upregulates SLC7A11 expression during RANKL-induced osteoclastogenesis; this SLC7A11 upregulation causes cystine accumulation when TXNRD1 is inhibited, leading to increased disulfide stress and disulfidptosis (not ferroptosis) in osteoclast precursors. Transcriptional analysis, NFATc1 ChIP/reporter assays, TXNRD1 inhibitor treatment, rescue with SLC7A11 inhibitors vs. ferroptosis inhibitors, OVX mouse model Redox biology Medium 37148740
2024 BAP1 tumor suppressor inhibits SLC7A11 expression (transcriptionally, via H2A deubiquitination); high SLC7A11 expression (or exogenous cystine) reverses BAP1-mediated protection against disulfidptosis, while SLC7A11 knockout or erastin treatment abrogates this protection, establishing SLC7A11-mediated cystine uptake as the key mediator of disulfidptosis sensitivity. Cell death inhibitor panel, disulfide bond accumulation in cytoskeleton proteins, SLC7A11 overexpression/knockout, genetic rescue experiments Oncogenesis Medium 39266549
2024 SIK1 phosphorylates HDAC5 at Ser498, promoting its interaction with 14-3-3 protein and protecting HDAC5 from TRIM28-mediated ubiquitylation; stabilized HDAC5 deacetylates STAT6, enhancing STAT6 transcriptional activity to upregulate SLC7A11, conferring ferroptosis resistance in pancreatic cancer. In vitro kinase assay, Co-IP, ubiquitination assay, ChIP, STAT6 acetylation analysis, PDAC organoids, PDX models Cancer letters High 40250791
2024 ALKBH5 m6A demethylase erases m6A modification from SLC7A11 mRNA, reducing its stability and expression; METTL3-mediated m6A modification of SLC7A11 mRNA at adenine +1795 is recognized by IGF2BP2, which promotes SLC7A11 mRNA stability; additionally, METTL3 decreases SLC7A11 protein ubiquitination through an m6A/YTHDF2/SOCS2 axis. MeRIP-qPCR, m6A site mapping, RIP (IGF2BP2), actinomycin D mRNA stability assay, ubiquitination assay, in vivo xenograft Cell death & disease Medium 39799112
2025 PRMT5 K240 lactylation (K240lac) directly inhibits transcription of ALKBH5 (m6A demethylase) via histone modifications (H4R3me2s and H3R8me2s), thereby boosting SLC7A11 mRNA m6A levels and stability to confer ferroptosis resistance in colorectal cancer; mutation at K240 disrupts these effects. Lactylation site mapping, ChIP (histone marks at ALKBH5 promoter), m6A analysis, mRNA stability assays, K240 mutagenesis, in vivo models Oncogene Medium 40447754
2024 ERO1α, a functional downstream target of mTORC1, stimulates SLC7A11 transcription by activating the IL-6/STAT3 pathway; a luciferase reporter and ChIP assay confirmed STAT3-mediated transcriptional activation of the SLC7A11 promoter downstream of ERO1α. RNA-sequencing, cytokine array, ELISA, ChIP, luciferase reporter assay, in vivo xenograft/organoid/PDX models Journal of experimental & clinical cancer research Medium 38610018
2024 AhR (aryl hydrocarbon receptor) transcriptionally regulates SLC7A11 expression; pharmacological inactivation or genetic ablation of AhR suppresses SLC7A11, enhancing erastin-induced ferroptosis; endogenous AhR ligand I3P protects cells from ferroptosis through an AhR/SLC7A11-dependent mechanism. Post-translational modifications of SLC7A11 during ferroptosis were also observed. AhR knockout/knockdown, pharmacological inhibition, reporter assays, ferroptosis induction, lipid peroxidation measurements Toxicology and applied pharmacology Medium 38641223
2024 CEBPG transcription factor directly binds to the SLC7A11 promoter and activates its transcription, suppressing ferroptosis in ovarian cancer; CUT&Tag and dual luciferase reporter assays confirmed direct transcriptional regulation. CUT&Tag, dual luciferase reporter assay, CEBPG knockdown, orthotopic mouse model, ferroptosis markers Journal of translational medicine Medium 37210575
2024 ATF4 transcription factor directly binds to the SLC7A11 promoter, increasing its transcription; dihydroartemisinin inhibits ATF4 expression, thereby reducing SLC7A11 transcription and promoting ferroptosis in HCC. ATF4 overexpression rescues DHA-induced ferroptosis. ATF4/SLC7A11 promoter binding assay, lentiviral overexpression rescue, lipid peroxidation assays, in vivo xenograft Journal of cellular and molecular medicine Medium 38652216
2024 RBM3 RNA-binding protein directly binds SLC7A11 mRNA (demonstrated by RNA pulldown and mass spectrometry); sodium butyrate promotes RBM3 expression, which indirectly downregulates SLC7A11 mRNA levels and promotes ferroptosis in endometrial cancer. RNA pulldown, mass spectrometry, transcriptome and metabolome analysis, in vivo xenograft Apoptosis Medium 37170022

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein & cell 1935 33000412
2019 Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer discovery 864 31554642
2018 Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer communications (London, England) 761 29764521
2020 Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis. Circulation research 637 32349646
2021 Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. Journal of experimental & clinical cancer research : CR 311 34162423
2023 ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. Journal of hepatology 290 36996941
2019 Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proceedings of the National Academy of Sciences of the United States of America 274 31000598
2018 xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene 269 29789716
2021 RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. The Journal of clinical investigation 260 34609966
2022 SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell death and differentiation 259 35995846
2021 Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cellular & molecular biology letters 231 34098867
2022 Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. Nature 228 35614212
2021 Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11. Cancer research 217 34385181
2022 The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer. Frontiers in oncology 197 35280777
2023 Baicalin induces ferroptosis in osteosarcomas through a novel Nrf2/xCT/GPX4 regulatory axis. Phytomedicine : international journal of phytotherapy and phytopharmacology 159 37209607
2022 STAT6 inhibits ferroptosis and alleviates acute lung injury via regulating P53/SLC7A11 pathway. Cell death & disease 158 35668064
2022 SLC7A11 as a Gateway of Metabolic Perturbation and Ferroptosis Vulnerability in Cancer. Antioxidants (Basel, Switzerland) 153 36552652
2022 The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clinical and translational medicine 147 35522946
2022 PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. International journal of biological sciences 139 36147463
2022 LncRNA HEPFAL accelerates ferroptosis in hepatocellular carcinoma by regulating SLC7A11 ubiquitination. Cell death & disease 135 36008384
2022 Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling. Molecular cell 132 35245456
2020 NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation. Genes & diseases 124 34522704
2021 HBx facilitates ferroptosis in acute liver failure via EZH2 mediated SLC7A11 suppression. Journal of biomedical science 112 34615538
2022 SHARPIN promotes cell proliferation of cholangiocarcinoma and inhibits ferroptosis via p53/SLC7A11/GPX4 signaling. Cancer science 111 35968603
2022 Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT. Gut 102 35086885
2023 Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 97 37867237
2023 TRIM3 facilitates ferroptosis in non-small cell lung cancer through promoting SLC7A11/xCT K11-linked ubiquitination and degradation. Cell death and differentiation 96 37978273
2021 KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma. Biochemical and biophysical research communications 86 33689883
2024 Role of SLC7A11/xCT in Ovarian Cancer. International journal of molecular sciences 85 38203758
2023 NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors. Redox biology 79 37148740
2023 Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis. Redox biology 79 38150993
2023 Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway. Redox biology 73 37984229
2011 Regulation of xCT expression and system x (c) (-) function in neuronal cells. Amino acids 73 21369940
2024 Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/GPX4 expression. Journal of experimental & clinical cancer research : CR 65 38600610
2022 The Role of SLC7A11 in Cancer: Friend or Foe? Cancers 64 35804831
2023 Resveratrol Alleviates Diabetic Periodontitis-Induced Alveolar Osteocyte Ferroptosis Possibly via Regulation of SLC7A11/GPX4. Nutrients 63 37432277
2024 AMPKα1-mediated ZDHHC8 phosphorylation promotes the palmitoylation of SLC7A11 to facilitate ferroptosis resistance in glioblastoma. Cancer letters 60 38211651
2024 Xanthohumol ameliorates drug-induced hepatic ferroptosis via activating Nrf2/xCT/GPX4 signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 58 38394733
2024 Targeting SIRT3 sensitizes glioblastoma to ferroptosis by promoting mitophagy and inhibiting SLC7A11. Cell death & disease 57 38395990
2024 Icariin inhibits chondrocyte ferroptosis and alleviates osteoarthritis by enhancing the SLC7A11/GPX4 signaling. International immunopharmacology 55 38636375
2023 Cigarette tar mediates macrophage ferroptosis in atherosclerosis through the hepcidin/FPN/SLC7A11 signaling pathway. Free radical biology & medicine 55 36933812
2023 miR-509-5p promotes colorectal cancer cell ferroptosis by targeting SLC7A11. Pathology, research and practice 55 37229918
2023 Mangiferin attenuates osteoporosis by inhibiting osteoblastic ferroptosis through Keap1/Nrf2/SLC7A11/GPX4 pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 54 38176266
2022 Capsaicin induces ferroptosis of NSCLC by regulating SLC7A11/GPX4 signaling in vitro. Scientific reports 49 35835852
2023 Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis. Apoptosis : an international journal on programmed cell death 48 37170022
2021 The ubiquitin hydrolase OTUB1 promotes glioma cell stemness via suppressing ferroptosis through stabilizing SLC7A11 protein. Bioengineered 44 34927544
2022 Functional role of the SLC7A11-AS1/xCT axis in the development of gastric cancer cisplatin-resistance by a GSH-dependent mechanism. Free radical biology & medicine 43 35367340
2015 Comparative analysis of antibodies to xCT (Slc7a11): Forewarned is forearmed. The Journal of comparative neurology 43 26494316
2023 Ferroptosis and Neurodegenerative Diseases: Insights into the Regulatory Roles of SLC7A11. Cellular and molecular neurobiology 42 36988772
2023 Macrophages originated IL-33/ST2 inhibits ferroptosis in endometriosis via the ATF3/SLC7A11 axis. Cell death & disease 41 37816731
2024 SLC7A11: the Achilles heel of tumor? Frontiers in immunology 40 39040097
2023 SLC7A11 promotes the progression of gastric cancer and regulates ferroptosis through PI3K/AKT pathway. Pathology, research and practice 39 37399587
2021 EZH2-mediated SLC7A11 upregulation via miR-125b-5p represses ferroptosis of TSCC. Oral diseases 39 34614259
2024 Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11. Journal of experimental & clinical cancer research : CR 38 38610018
2023 EGCG alleviates obesity-exacerbated lung cancer progression by STAT1/SLC7A11 pathway and gut microbiota. The Journal of nutritional biochemistry 38 37451475
2023 CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer. Journal of translational medicine 36 37210575
2023 Glial Glutamate Transporter-Mediated Plasticity: System xc-/xCT/SLC7A11 and EAAT1/2 in Brain Diseases. Frontiers in bioscience (Landmark edition) 35 37005761
2023 SLC7A11-associated ferroptosis in acute injury diseases: mechanisms and strategies. European review for medical and pharmacological sciences 35 37259719
2024 α-Ketoglutarate alleviates osteoarthritis by inhibiting ferroptosis via the ETV4/SLC7A11/GPX4 signaling pathway. Cellular & molecular biology letters 34 38877424
2024 Tanshinone IIA destabilizes SLC7A11 by regulating PIAS4-mediated SUMOylation of SLC7A11 through KDM1A, and promotes ferroptosis in breast cancer. Journal of advanced research 33 38615741
2024 Regulation of SLC7A11 as an unconventional checkpoint in tumorigenesis through ferroptosis. Genes & diseases 32 39569390
2023 The DUBA-SLC7A11-c-Myc axis is critical for stemness and ferroptosis. Oncogene 32 37537342
2024 SPTBN2 suppresses ferroptosis in NSCLC cells by facilitating SLC7A11 membrane trafficking and localization. Redox biology 31 38241838
2023 Nicorandil Regulates Ferroptosis and Mitigates Septic Cardiomyopathy via TLR4/SLC7A11 Signaling Pathway. Inflammation 31 38159178
2024 Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 30 38850659
2023 ALKBH5 decreases SLC7A11 expression by erasing m6A modification and promotes the ferroptosis of colorectal cancer cells. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 30 36820954
2019 Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension. American journal of respiratory cell and molecular biology 30 30897333
2023 The amino acid transporter SLC7A11 expression in breast cancer. Cancer biology & therapy 29 38073087
2025 SLC7A11 is an unconventional H+ transporter in lysosomes. Cell 28 40280132
2023 CircRNA circSTIL inhibits ferroptosis in colorectal cancer via miR-431/SLC7A11 axis. Environmental toxicology 27 36840697
2024 Gastrodin: Modulating the xCT/GPX4 and ACSL4/LPCAT3 pathways to inhibit ferroptosis after ischemic stroke. Phytomedicine : international journal of phytotherapy and phytopharmacology 25 39731833
2024 Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCT. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 24 39392373
2023 Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis. Apoptosis : an international journal on programmed cell death 24 38001343
2024 Essentiality of SLC7A11-mediated nonessential amino acids in MASLD. Science bulletin 23 39366830
2024 SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma. Frontiers in immunology 21 38655266
2024 Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment. Redox biology 21 39657365
2023 MiR-148a-3p Promotes Colorectal Cancer Cell Ferroptosis by Targeting SLC7A11. Cancers 20 37686618
2024 LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis. Oncogene 19 38605214
2024 Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway. Journal of cellular and molecular medicine 19 38652216
2024 Berberine Inhibits Ferroptosis and Stabilizes Atherosclerotic Plaque through NRF2/SLC7A11/GPX4 Pathway. Chinese journal of integrative medicine 19 39167283
2025 Nrf2 alleviates acute ischemic stroke induced ferroptosis via regulating xCT/GPX4 pathway. Free radical biology & medicine 18 40020881
2024 AhR signaling modulates Ferroptosis by regulating SLC7A11 expression. Toxicology and applied pharmacology 17 38641223
2024 Luteolin attenuates CCl4-induced hepatic injury by inhibiting ferroptosis via SLC7A11. BMC complementary medicine and therapies 17 38755566
2024 SLC7A11 in hepatocellular carcinoma: potential mechanisms, regulation, and clinical significance. American journal of cancer research 17 38859833
2024 Tumor suppressor BAP1 suppresses disulfidptosis through the regulation of SLC7A11 and NADPH levels. Oncogenesis 17 39266549
2023 The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance. The Journal of cell biology 17 37831441
2025 Galectin-13 reduces membrane localization of SLC7A11 for ferroptosis propagation. Nature chemical biology 16 40246981
2024 Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments. International journal of molecular sciences 16 39125853
2024 Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response. iMeta 16 39742309
2024 Magnolol against enterovirus 71 by targeting Nrf2-SLC7A11-GSH pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 15 38876045
2023 Hsa_circ_0070440 promotes lung adenocarcinoma progression by SLC7A11-mediated-ferroptosis. Histology and histopathology 15 36852950
2025 METTL3 inhibition promotes radiosensitivity in hepatocellular carcinoma through regulation of SLC7A11 expression. Cell death & disease 14 39799112
2025 SIK1 promotes ferroptosis resistance in pancreatic cancer via HDAC5-STAT6-SLC7A11 axis. Cancer letters 14 40250791
2025 PRMT5 K240lac confers ferroptosis resistance via ALKBH5/SLC7A11 axis in colorectal cancer. Oncogene 14 40447754
2023 TXNDC12 knockdown promotes ferroptosis by modulating SLC7A11 expression in glioma. Clinical and translational science 14 37503932
2019 High SLC7A11 expression in normal skin of melanoma patients. Cancer epidemiology 14 31419780
2024 HTRA1 interacts with SLC7A11 to modulate colorectal cancer chemosensitivity by inhibiting ferroptosis. Cell death discovery 13 38740771
2024 FMRP protects breast cancer cells from ferroptosis by promoting SLC7A11 alternative splicing through interacting with hnRNPM. Redox biology 13 39388855
2024 Chemerin attenuates acute kidney injury by inhibiting ferroptosis via the AMPK/NRF2/SLC7A11 axis. Communications biology 13 39702678
2023 NRF2 Antagonizes HIV-1 Tat and Methamphetamine-Induced BV2 Cell Ferroptosis by Regulating SLC7A11. Neurotoxicity research 13 37060393